New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
11:49 EDTTUP, TER, ONCY, GNC, CRRHigh option volume stocks: GNC TER CRR ONCY TUP
News For GNC;TER;CRR;ONCY;TUP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
06:34 EDTONCYOncolytics Biotech receives ODD from FDA for Reolysin
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation, or ODD, for its lead product candidate, Reolysin, for the treatment of primary peritoneal cancers. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication. On February 11, the company announced that it had received Orphan Drug Designation for ovarian cancer and for cancers of the fallopian tube on March 2.
06:32 EDTONCYOncolytics Biotech receives Orphan Drug Designation for Reolisyn
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation for its lead product candidate, Reolisyn, for the treatment of primary peritoneal cancers. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication.
March 2, 2015
06:38 EDTONCYOncolytics Biotech announces receipt of Orphan Drug Designatoin for REOLYSIN
Subscribe for More Information
06:37 EDTONCYOncolytics Biotech receives ODD from FDA for Reolysin
Subscribe for More Information
February 27, 2015
11:30 EDTTUPTupperware Brands management to meet with B. Riley
Subscribe for More Information
February 23, 2015
06:48 EDTTUPTupperware Brands volatility low into Q4 and outlook
Tupperware Brands March call option implied volatility is at 19, April is at 20, July is at 21; compared to its 26-week average of 22 according to Track Data, suggesting decreasing near term price movement into the expected release of Q4 results on February 25.
February 18, 2015
15:33 EDTTUPTupperware Brands to host analyst meeting
Subscribe for More Information
06:41 EDTONCYOncolytics Biotech completes enrollment of randomized Phase II study of REOLYSIN
Subscribe for More Information
06:37 EDTONCYOncolytics Biotech completes enrollment in Phase II colorectal cancer study
Subscribe for More Information
February 17, 2015
06:40 EDTONCYOncolytics Biotech receives ODD from FDA for REOLYSIN
Subscribe for More Information
06:36 EDTONCYOncolytics Biotech granted Orphan Drug Designation for REOLYSIN by FDA
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer. REOLYSIN is Oncolytics' proprietary isolate of the reovirus. Its primary mode of activity is to infect and selectively target tumours with activating Ras pathway mutations and/or over-expressions of Ras pathway elements including, amongst others, EGFR, BRAF and KRAS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use